George Poultsides
Overview
Explore the profile of George Poultsides including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
1721
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kawashima J, Akabane M, Endo Y, Woldesenbet S, Khalil M, Sahara K, et al.
Ann Surg Oncol
. 2025 Mar;
PMID: 40067612
No abstract available.
2.
Kawashima J, Endo Y, Woldesenbet S, Khalil M, Akabane M, Cauchy F, et al.
Ann Surg Oncol
. 2025 Mar;
PMID: 40067608
No abstract available.
3.
Kawashima J, Endo Y, Woldesenbet S, Khalil M, Akabane M, Cauchy F, et al.
Ann Surg Oncol
. 2025 Feb;
PMID: 39962005
Introduction: While postoperative adjuvant chemotherapy (AC) is generally recommended for intrahepatic cholangiocarcinoma (ICC), its benefit remains debated. This study aimed to identify patients that may benefit from AC following liver...
4.
Altaf A, Akabane M, Khalil M, Rashid Z, Zindani S, Kawashima J, et al.
HPB (Oxford)
. 2025 Feb;
PMID: 39956729
Background: We sought to determine the association between intraoperative blood loss (IBL) and postoperative morbidity among patients undergoing surgery for liver cancer. Methods: Patients undergoing surgery for primary and secondary...
5.
Kawashima J, Endo Y, Woldesenbet S, Khalil M, Akabane M, Cauchy F, et al.
HPB (Oxford)
. 2025 Feb;
PMID: 39915216
Introduction: We sought to define a cohort of patients with "biological R2" (bR2) resection, defined as recurrence within 12 weeks, following curative-intent resection for intrahepatic cholangiocarcinoma (ICC). In addition, we...
6.
Kawashima J, Akabane M, Endo Y, Woldesenbet S, Khalil M, Sahara K, et al.
Ann Surg Oncol
. 2025 Jan;
PMID: 39888467
Background: The feasibility of trials in liver surgery using a single-component clinical endpoint is low because single endpoints require large samples due to their low incidence. The current study sought...
7.
Altaf A, Khalil M, Akabane M, Rashid Z, Kawashima J, Zindani S, et al.
Eur J Surg Oncol
. 2025 Jan;
51(5):109594.
PMID: 39826445
Objective: We sought to develop a predictive model to preoperatively identify patients with hepatocellular carcinoma (HCC) at risk of undergoing futile upfront liver resection (LR). Methods: Patients undergoing curative-intent LR...
8.
Altaf A, Khalil M, Akabane M, Rashid Z, Kawashima J, Zindani S, et al.
HPB (Oxford)
. 2025 Jan;
27(3):402-413.
PMID: 39755480
Background: We sought to define textbook outcome in liver surgery (TOLS) for intrahepatic cholangiocarcinoma (ICC) by considering the implications of perioperative outcomes on overall survival (OS). Methods: Using a multi-institutional...
9.
Altaf A, Munir M, Khan M, Rashid Z, Khalil M, Guglielmi A, et al.
HPB (Oxford)
. 2025 Jan;
PMID: 39753458
Objective: We sought to develop a machine learning (ML) preoperative model to predict bile leak following hepatectomy for primary and secondary liver cancer. Methods: An eXtreme Gradient Boosting (XGBoost) model...
10.
Siy A, Zhou M, Boncompagni A, Charville G, Poultsides G, Ganjoo K
Cureus
. 2024 Dec;
16(11):e74837.
PMID: 39737274
Circulating tumor DNA (ctDNA) can be used to assess treatment response in patients with undifferentiated pleomorphic sarcoma (UPS). The importance of this is explored in our case of a 75-year-old...